Literature DB >> 18070930

Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin.

Radu Vasilcanu1, Daiana Vasilcanu, Bita Sehat, Shucheng Yin, Ada Girnita, Magnus Axelson, Leonard Girnita.   

Abstract

The initial event upon binding of insulin-like growth factor 1 to the insulin-like growth factor type-I receptor (IGF-1R) is auto-phosphorylation of tyrosine residues within the activation loop of the kinase domain followed by phosphorylation of other receptor tyrosine residues and the subsequent activation of the intracellular signaling cascades. We found recently that the cyclolignan picropodophyllin (PPP) inhibits phosphorylation of IGF-1R and phosphatidyl-3 kinase/Akt (protein kinase B) signaling molecules without interfering with the highly homologous insulin receptor. Furthermore, PPP causes regression of tumor grafts and substantially prolongs the survival of animals with systemic tumor disease. It is of interest that we show here that short treatments with PPP activate the intracellular extracellular signal-regulated kinase (ERK) signaling. Our data suggest that PPP induces IGF-1R ubiquitination and in turn activates ERK1/2. The PPP-induced ERK activation requires IGF-1R because PPP is not able to induce ERK phosphorylation in IGF-1R-negative cells or in cells in which the receptor is knocked down by small interfering RNA. Moreover, in the absence of Mdm2, an E3 ligase that has been shown previously to be involved in IGF-1R ubiquitination, the phosphorylation of ERK did not occur. Thus, apart from inhibiting the receptor activity, PPP can induce IGF-1R ubiquitination and stimulate ERK in an Mdm2-dependent manner. This response could contribute to the apoptotic effect of PPP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070930     DOI: 10.1124/mol.107.040014

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  22 in total

1.  Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor.

Authors:  Huiyuan Zheng; Claire Worrall; Hongchang Shen; Tarik Issad; Stefan Seregard; Ada Girnita; Leonard Girnita
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

2.  IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma.

Authors:  Dawei Song; Sonia Cismas; Caitrin Crudden; Eric Trocme; Claire Worrall; Naida Suleymanova; Tingting Lin; Huiyuan Zheng; Stefan Seregard; Ada Girnita; Leonard Girnita
Journal:  Oncogene       Date:  2021-11-17       Impact factor: 9.867

3.  IGF-IR and its inhibitors in gastrointestinal carcinomas (Review).

Authors:  Xiao Hong Bao; Yoshio Naomoto; Hui Fang Hao; Nobuyuki Watanabe; Kazufumi Sakurama; Kazuhiro Noma; Takayuki Motoki; Yasuko Tomono; Takuya Fukazawa; Yasuhiro Shirakawa; Tomoki Yamatsuji; Junji Matsuoka; Munenori Takaoka
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

Review 4.  Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.

Authors:  Quanri Jin; Francisco J Esteva
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

5.  β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.

Authors:  Huiyuan Zheng; Hongchang Shen; Iulian Oprea; Claire Worrall; Radu Stefanescu; Ada Girnita; Leonard Girnita
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-27       Impact factor: 11.205

6.  Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: clinical implications.

Authors:  Xiaoying Feng; Eiman Aleem; Yingbo Lin; Magnus Axelson; Olle Larsson; Thomas Strömberg
Journal:  Int J Oncol       Date:  2011-12-06       Impact factor: 5.650

7.  Insulin-like growth factor-I E-peptide activity is dependent on the IGF-I receptor.

Authors:  Becky K Brisson; Elisabeth R Barton
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

8.  Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP).

Authors:  Jamileh Hashemi; Claire Worrall; Daiana Vasilcanu; Mårten Fryknäs; Luqman Sulaiman; Mohsen Karimi; Wen-Hui Weng; Weng-Onn Lui; Christina Rudduck; Magnus Axelson; Helena Jernberg-Wiklund; Leonard Girnita; Olle Larsson; Catharina Larsson
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

9.  Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor.

Authors:  A Girnita; H Zheng; A Grönberg; L Girnita; M Ståhle
Journal:  Oncogene       Date:  2011-06-20       Impact factor: 9.867

10.  Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma.

Authors:  Zheng Liang; Arjan Diepstra; Chuanhui Xu; Gustaaf van Imhoff; Wouter Plattel; Anke Van Den Berg; Lydia Visser
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.